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Metabolic syndrome is a co-occurrence of obesity, insulin resistance, hypertension, and dyslipidemia caused by improper 
diet and lifestyle. Arogyavardhini compound (AVC) contains an equal quantity of Arogyavardhini rasa and Lasuna powder. 
In clinical practice, Arogyavardhini Rasa is well known for its antidyslipidemic and weight lowering effect. Therefore, the 
present experimental study was designed to evaluate the safety of AVC on acute administration and anti-dyslipidemic 
activity in albino rats. An acute oral toxicity study for AVC was carried out by following OECD 425 guidelines. The anti-
dyslipidemic activity was carried out against fructose-induced dyslipidemia in albino rats. No mortality and toxicity were 
observed and gross behaviours of all the albino rats were found normal during the experimental period of 14 days in the 
acute toxicity study. Fructose significantly increased blood sugar, triglycerides, SGPT, and alkaline phosphatase levels in 
albino rats in comparison to the control group. AVC treated group produced a decrease in serum triglyceride, transaminases, 
and alkaline phosphatase, which suggest that the drug has potential as anti-dyslipidemic and may be protective for 
degenerative changes produced by fructose in the liver, kidney, and heart of albino rats. From the present study it is 
concluded that AVC is safe up to an oral dose of 2000 mg/kg in albino rats and has exhibited a protective role in fructose-
induced dyslipidemia in albino rats, hence may be useful in metabolic syndrome. 
Keywords: Acute toxicity, Antidyslipidemic activity, Arogyavardhini compound, Fructose, Metabolic syndrome. 
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Introduction 
Metabolic syndrome, a combined occurrence of 
three or more metabolic disorders including obesity, 
insulin resistance, hypertension and dyslipidemia 
which are caused by improper diet and lifestyle and is 
recognized as one of the major public health burdens 
worldwide especially in the Indian sub-continent
1,2
. It 
is estimated that approximately 25% of the world's 
population has metabolic syndrome and it will 
increase up to 38% by 2023
 3
. The prevalence of this 
syndrome is higher in the adult population throughout 
the world
4
. In the etiopathogenesis of metabolic 
syndrome, reactive oxygen species (ROS) play an 
essential role in multiple systems and contribute to 
cellular metabolic dysfunction. Oxidative stress plays 
a major role in the pathogenesis of a variety of 
human diseases, including diabetes, hypertension, 




Arogyavardhini compound (AVC) is a herbo-
mineral formulation that contains an equal quantity of 
Arogyavardhini rasa and Lasuna (Allium ascalonicum 
L.) powder. It is developed for the treatment of 
metabolic disorders. Arogyavardhini Rasa is having 
Deepana (appetizer), Pachana (digestive) properties 
and being indicated for Medodosha (fat metabolism 
disturbance) as well as Lasuna (Garlic) being 
indicated for Avaran (obstruction) of Vata, So 
the combination of both is expected to remove 
Medodosha correcting Agni and the function of Vata 
by removing Avaran, which are the main culprits 
in the pathogenesis of disease
6,7
. Recent researches 
on Arogyavardhini Rasa have proved its 




lipidemic, anticancer and antioxidant effects of 
Lasuna are also proven by various researches
9,10
. So, 
AVC is expected to establish its role, especially on 
dyslipidemia conditions with the presence of other 
components of metabolic syndrome together. The 









safety of AVC in acute toxicity study and anti-
dyslipidemic activity in albino rats for documentation 
of scientific data on the safety and efficacy of AVC. 
 
Materials and Methods 
 
Animals 
Charle’s foster strain albino rats of either  
sex weighing between 200±20 g were used for 
experiments. The animals were obtained from the 
Animal house attached to the Pharmacology 
laboratory. They were exposed to 12 hours of light 
and dark cycles, with ideal husbandry conditions in 
terms of ambient temperature and humidity. The 
temperature during the experiment was between 23±3 
ºC and humidity around 50-60%. Animals were fed ad 
libitum with Amrut brand rat pellet feed supplied by 
Pranav Agro Industries and drinking water. The 
experiment as per the guideline of CPCSEA, India 
was carried out after obtaining the permission from 
Institutional Animal Ethics Committee (IAEC/ 
17/2015/07). 
 
Drugs and Chemicals 
AVC is a herbo-mineral non-classical Ayurvedic 
formulation. It was developed by authors consists of 
Arogyavardhini rasa with Lasuna for the treatment of 
metabolic disorders. Table 1 depicts the ingredients of 
AVC
11
. Lasuna was procured from the garlic and 
onion market of Ahmedabad, Gujarat. Raw drugs of 
Arogyavardhini Rasa were collected from the 
Pharmacy, Gujarat Ayurveda University, Jamnagar, 
Gujarat, India. Raw drugs were identified and 
authenticated in the Pharmacognosy Laboratory of the 
Institute for Post Graduate Teaching and Research in 
Ayurveda, Gujarat Ayurveda, University, Jamnagar. 
The identification was carried out based on 
organoleptic characters and microscopic characters of 
Churna and later on pharmacognostical evaluation of 
the AVC was carried out. The microphotographs were 
also taken under the microscope. The formulation was 
prepared and pharmaceutical analysis of the finished 
product was carried out as per API parameters for 
quality compliance
12
. All other chemicals used were 
of analytical grade. 
 
Dose fixation 
The therapeutic clinical dose of AVC is considered 
as 1 g twice a day for the treatment of metabolic 
disorders
13
. Based on that, the dose of animals was 
calculated by extrapolating the human therapeutic 
dose to rat dose (conversion factor 0.018 for 200 g 
rat) based on body surface area ratio by referring to 
table of Paget and Barnes (1964)
14
. Considering that, 
rat therapeutic dose was calculated as 90 mg/kg body 
weight twice a day.  
 
Route of drug administration 
The suspension of the test drug was prepared with 
distilled water to suitable concentration and in 
uniform volume was administered by oral route with 
the help of oral feeding cannula. The test drug was 
administered daily between 9:30 to 10:30 am and 4:30 
to 5:30 pm. 
 
Acute oral toxicity study 
Acute oral toxicity study of AVC was carried out 





 March 2006) with 2000 mg/kg as a 
limit test. Five female albino rats in each group were 
treated with 2000 mg/kg sequentially and rats were 
observed for 14 days. AVC (limit dose) was 
administered once orally to overnight fasted rats. 
Gross behaviour and mortality, if any was observed 
Table 1 — The ingredients of AVC 
Name of drug  Latin name  Part used  Ratio  Form  
Suddha Parada  -  -  1 part  Powder  
Suddha Gandhaka - - 1 part Powder 
Loha bhasma  -  -  1 part  Bhasma  
Abharaka bhasma  -  -  1 part  Bhasma  
Tamra bhasma  -  -  1part  Bhasma  
Haritaki  Terminalia chebula L.  Fruit  2 part  Powder 
Amalaki  Emblica officinalis L.  Fruit  2 part  Powder 
Bibhitaki  Terminalia bellirica R. Fruit  2 part  Powder 
Suddha Shilajatu  -  Exudates  3 part  Powder 
Suddha Guggulu  Commiphora mukul H.  Gum  4 part  Powder 
Eranda moola  Ricinus communis L. Root  4 part  Powder 
Katuki  Picrorhiza kurrora R. Root/Rhizome  22 part  Powder 
Nimba patra svarasa  Azadirachta indica A.  Leaves Juice  Mardana for 2 days 
Single bulb Lasuna  Allium ascalonicum L.  Bulb  44 part  Churna  
 




throughout the study period for 14 days. Food was 
withheld overnight before the experiment and further 
2 hours after administration of the test drug. 
The animals were observed continuously for  
6 hours after the dosing. The careful cage side 
observation was done without disturbing the animal 
attention and at the end of every hour, animals were 
individually exposed to an open arena for recording 
the behavioural changes like increased or decreased 
motor activity, convulsions, Straub's reactions,  
muscle spasm, catatonia, spasticity, opisthotonus, 
hyperesthesia, muscle relaxation, anaesthesia, arching 
and rolling, lacrimation, salivation, diarrhoea, 
writhing, mode of respiration, changes in skin colour, 
exitus, C.N.S. depression- hypoactivity, passivity, 
relaxation, ataxia, and narcosis etc. All the animals 
were observed at ½, 1, 2, 3, 4, 5, 6, 24 hours after 
administration of test drug and daily once for any 
mortality during the experimental period (14 days). 
The body weight of each animal was recorded just 
before treatment on days 1, 7 and 14. 
 
Anti-dyslipidemic activity 
Charle’s foster strain albino rats of either sex 
weighing 200±20 g were randomly divided into four 
groups, each consisting of six rats (n=6). Group I 
received Normal control rats received distilled water 
(10 mL/kg, po) (NC), Group II Fructose control rats, 
received distilled water (10 mL/kg, po) + 10% 
fructose in drinking water (FRC), Group III, treated 
group received AVC (90 mg/kg/day, po) + 10% 
fructose in drinking water (AVC), and Group IV 
Pioglitazone (10 mg/kg/day, po) + 10% fructose in 
drinking water. 
Test drugs and reference standard drugs were 
administered to respective groups for 30 days. 
Pioglitazone was used as a standard drug for anti-
dyslipidemic activity and the dose was fixed at  
10 mg/kg/day
16
. The 10% w/v fructose solution was 
given in drinking water ad libitum for 24 hours during 
the study period of 30 days in all the groups to induce 
dyslipidemia except in the normal control (Group I). 
Chronic fructose feeding is associated with insulin 





day, after overnight fasting, the rats 
were weighed again and blood was collected from 
retro-orbital puncture under light ether anaesthesia. 
Serum was separated and used for estimation of 
different serum biochemical parameters like total 
cholesterol, triglyceride, HDL-cholesterol, fasting 
blood glucose, SGPT, and alkaline phosphatase, using 
a fully automated biochemical random-access 
analyzer (BS-200, Lilac Medicare Pvt. Ltd., Mumbai). 
In the end, the rats were sacrificed and important 
organs were dissected such as the liver, kidney, and 
heart. The organs were cleaned of extraneous tissue, 
weighed immediately and then transferred to a 10% 
buffered formalin solution for fixing. They were 
processed later for histopathological studies.  
 
Statistical analysis 
The data are expressed as Mean±SEM for six rats 
in each group. Statistical comparisons were performed 
by Student’s Paired and Unpaired ‘t’ test and one-way 
ANOVA followed by Dunnett’s multiple ‘t’ test by 
using Sigma stat software (version 3.1) for all the 
treated groups with the level of significance set at  
P <0.05. 
 
Results and Discussion 
 
Acute oral toxicity study 
OECD 420, 423, and 425 guidelines were 
employed using a single-sex (preferably females) to 
reduce variability and as a means of minimizing the 
number of animals used. This is because literature 
surveys of conventional LD50 tests show that usually 
there is little difference in sensitivity between the 
sexes but, in those cases where differences were 
observed, females were generally slightly more 
sensitive
17
. Hence, in the present study, acute toxicity 
was evaluated in female albino rats. AVC at a dose 
level of 2000 mg/kg orally did not produce any 
mortality in any of the treated rats which suggest that 
LD50 value may be higher than 2000 mg/kg by oral 
route. In the present study, normal progressive weight 
gain was observed in both normal control and treated 
groups in comparison to the initial weight. As per UN 
classification, any substance which has oral LD50 of 
more than 2000 mg/kg is considered as low hazard 
potential. Thus, as per the above criterion, the AVC 
can be categorized as a substance with low health 
hazard potential (Class 4 of Globally Harmonized 





Lipid pathology in human beings is quite similar to 
fructose-induced dyslipidemia in animals, so the 
fructose-induced dyslipidemia model is considered a 
suitable model to evaluate anti-dyslipidemic activity 
in experimental models. Fructose results in obesity 
and weight gain through several mechanisms
19
. In a 
clinical study, Havel’s et al. observed that fructose 




does not cause a level of satiety equivalent to that of a 
glucose-based meal
20
. Specifically, the differences in 
the effect of fructose and glucose consumption 
(consumed as beverages with three meals) on ad 
libitum food intake and hunger rating were observed 
on the day after the exposure to the sweetened 
beverages. Fructose is not able to stimulate insulin 
and leptin and inhibit the ghrelin which may affect the 
satiety centre in the central nervous system. In the 
present study, administration of 10% fructose solution 
led to a significant increase in body weight of fructose 
control group albino rats when compared to normal 
control rats. AVC attenuated the fructose-induced 
weight gain in albino rats (Table 2). This indicates 
that the test drug has antagonizing effect against 
fructose-induced changes in body weight. Fructose 
consumption leads to a non-significant increase in 
liver weight and a significant decrease in kidney 
weight in comparison to the normal control group. 
AVC did not produce any effect on the relative weight 
of liver, kidney, and heart of albino rats (Table 3). 
Fructose consumption in high amounts leads  
to postprandial hypertriglyceridemia and visceral 
adipose deposition contributing to hepatic triglyceride 
accumulation and protein kinase C activation. 
Fructose initiates hepatic insulin resistance 
independently of visceral adiposity and free fatty acid 
delivery
21
. It has been found that hepatic production 
of triglycerides is much greater with fructose 
consumption as compared with equimolar 
concentrations of glucose consumption
22
. Fructose is 
metabolized in the liver and having less ability of 
expression of the fructose transporter GLUT5 in 
pancreatic β-cells does not stimulate insulin 
secretion
23
. Consumption of fructose-sweetened 
beverages with meals produced a rapid and prolonged 
elevation of plasma triglycerides and Apolipoprotein 
B compared with glucose-sweetened beverages
24
. 
Fructose increases the incidence of hypertension, non-
alcoholic fatty liver diseases and diabetes
25
. 
A significant increase in serum triglyceride and an 
insignificant increase in serum cholesterol were 
observed in the fructose control group in comparison 
to the normal control group. Treatment with AVC 
attenuated the increased serum level of triglyceride 
and cholesterol level but did not affect HDL-
cholesterol level when compared to the fructose 
control group (Table 4) which may suggest anti-
hyperlipidemic activity in rats. Tamra (Copper)  
is one of the important components of AVC.  
Recent research works on copper indicates that  
copper deficiency is associated with specific  
effects on systemic lipid metabolism
26
. Early work 
showed feeding rats with a copper-deficient diet 
revealed hypercholesterolemia, cardiac hypertrophy, 
haemorrhage, inflammation, and focal necrosis
27
. The 







 possess antihyperlipidemic activity which 
is believed to play a significant role in the decrease of 
serum cholesterol and triglycerides in AVC treated 
group. 
Table 2 — Effect of test drugs on body weight of albino rats 
during anti dyslipidemic study 
Treatments Body weight (g) 
Initial Final % change 
NC 176.67±9.72 202.50±11.80* 14.62↑ 
FRC 170.00±8.94 228.33±12.76** 34.31↑ 
AVC 182.00±14.63 232.00±17.72** 27.47 ↑ 
Pioglitazone 179.00±4.28 238.33±10.05** 33.14 ↑ 
Data: MeanSEM;↑-Increase; *P <0.01; **P <0.001 when compared 
to initial body weight (Paired ‘t’ test) 
 
Table 3 — Effect of test drugs on the relative weight of organs of 
albino rats during anti dyslipidemic study 
Treatments Relative weight 
Liver  
(g/100 g BW) 
Heart  
(mg/100 g BW) 
Kidney  
(mg/100 g BW) 
NC 3.1220.127 311.4914.36 705.8117.06 
FRC 3.3740.115 308.836.55 626.0626.22* 
AVC 3.0770.057 293.928.49 652.9141.74 
Pioglitazone 3.5210.201 301.5916.45 625.0337.83 
Data: MeanSEM; ↑- Increase; ↓- Decrease; *P <0.05 when 
compared to normal control group (Unpaired ‘t’ test) 
 
Table 4 — Effect of test drugs on blood sugar, cholesterol and triglyceride levels in albino rats during anti-dyslipidemic study 












Control 69.833±5.32 -- 43.33±4.31 -- 65.33±12.16 -- 
FRC 118.67±13.59@ 69.93↑ 49.67±4.99 14.63↑ 148.17±27.12@ 126.80↑ 
AVC 115.75±11.56 2.46 ↓ 45.00±3.66 9.40↓ 102.50±34.03 30.82↓ 
Pioglitazone 108.33±7.07 8.71 ↓ 50.67±3.49 16.93↑ 77.83±11.48# 47.47↓ 
Data: MeanSEM; ↑-Increase; ↓ - Decrease; @P <0.05, when compared to the normal control group (Annova followed by Dunnett’s 
multiple ‘t’ test); #P <0.05, when compared to the fructose control group (Unpaired ‘t’ test). 
 




Hypolipidemic activity of guggulsterone present in 
Guggulu can be explained through several 
mechanisms, like removal of excess cholesterol from 
the body through conversion of cholesterol to bile 
acids and subsequent excretion through the entero-
hepatic circulation pathway
31
. Inhibition of HMG-
CoA reductase and 14-alpha-demethylase reduction 




AVC did not affect the BSL in comparison to the 
fructose control group (Table 4). However, Katuki  
is also an ingredient of AVC, which is in larger 
quantity in Arogyavardhini rasa, which possesses 
anti-hyperglycemic activity. Aqueous extract of 
Picrorhiza kurroa increases the insulin-mediated 
translocation of GLUT-4 from the cytosol to the 
plasma membrane and increase glucose uptake by 
skeletal muscles and improves glycaemic control
33
. 







 also possess antihyperglycemic 
activities.  
There was a significant elevation of SGPT and 
alkaline phosphatase levels in the fructose control 
group (Table 5). The liver contains the highest 
amount of SGPT in comparison to other tissues. 
Elevation of SGPT is indicative of liver injury due to 
leakage of this enzyme from the tissue into the serum. 
An increased level of alkaline phosphatase suggests 
obstructive liver damage. Treatment with AVC 
attenuated the increased levels of SGPT and alkaline 
phosphatase in albino rats, which suggest the hepato-
protective role of the drug in fructose-induced 
dyslipidemia in rats. 
Overall, the AVC reduced triglyceride, 
transaminase, and alkaline phosphatase, which 
suggest that the drug has potential as anti-
dyslipidemic and may be protective for degenerative 
changes produced by 10% fructose in the liver, 
kidney, and heart of albino rats. The results of 
biochemical parameters corroborate with the 
histopathological study. The histopathological study 
also clearly indicates the presence of pathological 
changes in liver, kidney, and heart of fructose treated 
rats whereas the AVC prevented dyslipidemia-
induced pathological changes in these organs  
(Fig. 1-3).  
Further, the AVC is having Triphala as one of the 
contents, which is a well-known drug having rich 
antioxidants, antihyperlipidemic, cardioprotective, 
and many more pharmacological activities. 
Ingredients of Triphala are reported with different 
pharmacological actions. Haritaki is reported to have 
antioxidant
37
 and cardioprotective actions
38
. Bibhitaki 














Thus, the observed anti-dyslipidemic activity of the 
AVC may be attributed to the involvement of one or 
more mechanisms viz., by interfering with the 
absorption of the cholesterol from dietary sources, by 
interfering with the re-esterification or incorporation 
 
 
Fig. 1 — Photomicrographs of representative sections of Liver 
taken at x 400 magnification. a) Normal cytoarchitecture (Normal 
control group), b) Sinusoidal inflammation, fatty changes and 
necrosis (fructose control group), c) Mild fatty changes (AVC 
treated group), and d) Almost normal cytoarchitecture 
(Pioglitazone treated group). 
 
Table 5 — Effect of test drugs on HDL-cholesterol, SGPT and Alkaline phosphatase levels in albino rats during anti-dyslipidemic study 
Treatments HDL-cholesterol 
(mg/dL) 
% change SGPT 
(IU/L) 
% change ALP (IU/L) % change 
Control 31.16±1.72 -- 43.16±1.42 -- 106.66±9.71 -- 
FRC 37.83±5.06 19.67↑ 65.83±5.75@ 52.52↑ 241.33±37.59@ 126.26↑ 
AVC 41.60±9.15 9.96↑ 60.40±2.84 8.24↓ 196.80±11.91 18.45↓ 
Pioglitazone 36.33±2.39 3.96↓ 75.50±2.77 14.68↑ 220.83±28.22 8.49↓ 
Data: MeanSEM; ↑-Increase; ↓ - Decrease; @P <0.05, when compared to the normal control group (Annova followed by Dunnett’s 
multiple ‘t’ test) 
 




of fatty acids to form chylomicrons in the intestinal 
epithelial cells, by interfering with the formation of 
endogenous triglycerides in the tissues by inhibiting 
the enzyme diacylglycerol transferase, by interfering 
with the transport of triglycerides from the 
endoplasmic reticulum to a microsomal site which is 
by microsomal triglyceride transport protein, by 
inhibiting the activity of the lipoprotein lipase at 
different sites, or by inhibiting the activity of the rate-
limiting enzyme in cholesterol bio-synthesis- HMG-
CoA (3-hydroxy 3-methyl 3-methylglutaryl CoA). 
 
Conclusion 
From the present study, it is concluded that the 
Arogyavardhini compound is safe up to an oral dose 
of 2000 mg/kg in albino rats. It has a protective role 
in fructose-induced dyslipidemia in albino rats, hence 
may be useful in metabolic syndrome. 
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